Ultragenyx Pharma (RARE) Reports Q4 Loss of $0.37 on Revenues of $91.54M

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($0.37), versus ($1.62) reported last year. Revenue for the quarter came in at $91.54 million, versus $35.59 million reported last year.

“Last year was a transformative year as we received two approvals, generated clinically meaningful data in our gene therapy and antisense oligonucleotide programs, and completed several strategic business development transactions,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “In addition to growing our global commercial footprint in 2021, we will also have a strong, diverse, late-stage clinical development portfolio. We will initiate three pivotal gene therapy studies, a fourth pivotal study with our recently in-licensed biologic, setrusumab, for osteogenesis imperfecta, make additional progress in the Angelman syndrome study, and bring our first mRNA program to the clinic for glycogen storage disease type III.”

2021 Financial Guidance

Crysvita Guidance in Ultragenyx TerritoriesThe company reaffirms the 2021 guidance range for Crysvita that was provided at the beginning of the year. This range is $180 million to $190 million for the North American profit share region and the other regions where product sales are recognized (Latin America and Turkey).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Nanometrics (NANO) Issues Business Update, Reports FY23 Results
• IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
• Live Oak Bancshares, Inc. (LOB) Misses Q1 EPS by 11c